JPS63267724A - Dermatitis treating liquid composition - Google Patents
Dermatitis treating liquid compositionInfo
- Publication number
- JPS63267724A JPS63267724A JP10015887A JP10015887A JPS63267724A JP S63267724 A JPS63267724 A JP S63267724A JP 10015887 A JP10015887 A JP 10015887A JP 10015887 A JP10015887 A JP 10015887A JP S63267724 A JPS63267724 A JP S63267724A
- Authority
- JP
- Japan
- Prior art keywords
- liquid composition
- dissolved
- skin diseases
- carbon dioxide
- alkaline earth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 201000004624 Dermatitis Diseases 0.000 title abstract 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 18
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 9
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 9
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910001448 ferrous ion Inorganic materials 0.000 claims abstract description 7
- 229910001385 heavy metal Inorganic materials 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000007864 aqueous solution Substances 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims abstract description 3
- 208000017520 skin disease Diseases 0.000 claims description 15
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
- 159000000014 iron salts Chemical class 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 229910052788 barium Inorganic materials 0.000 claims 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052712 strontium Inorganic materials 0.000 claims 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 abstract description 13
- 201000004647 tinea pedis Diseases 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 4
- 239000003929 acidic solution Substances 0.000 abstract description 2
- 230000033116 oxidation-reduction process Effects 0.000 abstract description 2
- 239000003513 alkali Substances 0.000 abstract 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
- 230000000249 desinfective effect Effects 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
- 150000002505 iron Chemical class 0.000 abstract 1
- -1 alkaline earth metal salts Chemical class 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical class [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 206010024380 Leukoderma Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000008334 Pisonia alba Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
(イ)技術分野
本発明は水虫等の皮膚病治療用の液組成物に関するもの
である。DETAILED DESCRIPTION OF THE INVENTION (a) Technical Field The present invention relates to a liquid composition for treating skin diseases such as athlete's foot.
(ロ)発明の背景
皮膚病は一般的によく経験するところであり、特に多湿
な我国においてはいわゆる水虫が特に多い、この水虫は
一般的な病気であるが、その反面重大な事態に至ること
も殆んどないために、その効果的な治療薬の開発が遅れ
ているのが現状である。(b) Background of the Invention Skin diseases are commonly experienced, and athlete's foot is particularly common in our humid country. Although athlete's foot is a common disease, it can also lead to serious problems. Currently, the development of effective therapeutic drugs is delayed because there are very few.
水虫は白霧菌による皮膚病であって、該菌はケラチンか
らなる皮膚外側の熱や寒気さらに化学薬品にも強い角質
層に好んで繁殖し、この角質層を食い破り、人体に不快
感を与える。Athlete's foot is a skin disease caused by a white fog fungus, and the fungus prefers to breed in the stratum corneum, the outer layer of the skin made of keratin that is resistant to heat, cold, and chemicals, and rips through this stratum corneum, causing discomfort to the human body. give.
水虫の治療薬としては、液状のもの、軟膏状のものある
いは丸薬状のものがあり、前2者は比較的軽度の水虫殺
菌用として使用されており、また後者は重度の水虫すな
わち風下等に発生した水虫殺菌用の内服剤として市販さ
れている。Treatments for athlete's foot include liquids, ointments, and pills.The former two are used to kill relatively mild athlete's foot, and the latter is used to treat severe athlete's foot, such as downwind. It is commercially available as an internal medicine for killing athlete's foot.
しかしながら、内服剤は副作用があるため、特に医師の
許可がないと入手することができない。However, oral preparations have side effects and cannot be obtained without a doctor's permission.
また、皮膚面に塗布塗着する液状または軟膏状のものの
効果は通常余りかんばしくなく、仮に一時的に癒すこと
ができたかに見えても、すぐ再発する。これは白−菌を
完全に殺菌していないためであり、ただ肉眼では治った
かに見えるに過ぎない。In addition, the effects of liquid or ointment materials applied to the skin are usually not very effective, and even if it appears to be temporarily cured, it will soon recur. This is because the white bacteria has not been completely sterilized, and to the naked eye it just looks like it has been cured.
(ハ)発明の開示
本発明はこのような実情にかんがみ、副作用のおそれが
なく、即効性を持ち、皮膚病の病原菌例えば白癖菌をほ
ぼ完全に殺菌でき、かつコスト的にも比較的安価な皮膚
病治療用の液組成物の開発を目的としてなされたもので
ある。(C) Disclosure of the Invention In view of the above circumstances, the present invention has been developed to provide a method that has no fear of side effects, is immediately effective, can almost completely kill pathogenic bacteria of skin diseases, such as leukoderma, and is relatively inexpensive. The aim was to develop a liquid composition for the treatment of skin diseases.
この目的において、本発明者は数多くの試験研究と臨床
実験を重ねた結果、ここにこの目的をほぼ達成できる新
規な水虫等の皮膚病治療用液組成物を完成することがで
きた。For this purpose, the present inventor has conducted numerous test studies and clinical experiments, and as a result has now completed a novel liquid composition for treating skin diseases such as athlete's foot, which can substantially achieve this purpose.
即ち1本発明の皮膚病治療用液組成物は、第1鉄イオン
と二酸化炭素を溶存した還元性雰囲気の硫酸酸性溶液を
主成分とするものである。Specifically, the liquid composition for treating skin diseases of the present invention has as its main component a sulfuric acid acidic solution in a reducing atmosphere in which ferrous ions and carbon dioxide are dissolved.
更に詳しくは、第1鉄イオン30 g / 1以上。More specifically, ferrous ion 30 g/1 or more.
二酸化炭素40cc/文以上を溶存するように鉄塩と炭
酸塩を水に溶解し、さらにアルカリ金属、アルカリ土金
属および重金属(周期率表に示す工。Dissolve iron salts and carbonates in water to dissolve at least 40 cc/liter of carbon dioxide, and add alkali metals, alkaline earth metals, and heavy metals (as shown in the periodic table).
■、■又は■族)の少なくとも1種以上の塩を溶解させ
た還元性雰囲気の硫酸酸性水溶液を主成分とし、全5o
42−イオンが200 g/交以下であり、pH値を4
.0以下に調整した液組成物である。The main component is a sulfuric acid acidic aqueous solution in a reducing atmosphere in which at least one salt of the group ①,
42-ion is below 200 g/cross and the pH value is 4.
.. This is a liquid composition adjusted to 0 or less.
本発明の皮膚病治療用液組成物を用いて治癒させた臨床
例については後述の実施例において詳述するが、本発明
の基本的な特徴は第1鉄イオン及び二酸化炭素と、必要
によりアルカリ金属塩、アルカリ土金属塩又は重金属塩
の存在下で、鉄の酸化還元反応を進行させ白寥菌等の皮
膚病の病原菌を殺菌せしめるようにした点にある。Clinical cases cured using the liquid composition for treating skin diseases of the present invention will be described in detail in the examples below, but the basic features of the present invention are that ferrous ions and carbon dioxide, and if necessary, alkaline In the presence of metal salts, alkaline earth metal salts, or heavy metal salts, the oxidation-reduction reaction of iron proceeds to kill pathogenic bacteria of skin diseases such as P. alba.
液は還元性雰囲気を示す硫酸酸性の液組成物であって、
二酸化炭素40cc/文以上(N、T、P。The liquid is a sulfuric acid acidic liquid composition exhibiting a reducing atmosphere,
Carbon dioxide 40cc/liter or more (N, T, P.
で)、pH値4.0以下好ましくは2.0〜3.5であ
る。換言すれば、二酸化炭素、硫酸第1鉄塩および還元
性雰囲気が相乗効果的に作用して白癖菌等の病原菌が殺
菌されるものと考えられる。), the pH value is 4.0 or less, preferably 2.0 to 3.5. In other words, it is thought that carbon dioxide, ferrous sulfate salt, and the reducing atmosphere act synergistically to kill pathogenic bacteria such as Alterinibacterium.
硫酸第1鉄塩の溶存量は殺菌効果を著しく向上させる上
で適切な範囲に調節されねばならず、また殺菌又は塗布
上補助剤となると考えられるアルカリ金属塩、アルカリ
土金属塩又は重金属塩の全塩類の合計が全5OIL2−
Jlで示してSO〜200g/交の範囲、好ましくは7
0−1SOg/文の範囲とする必要がある。The amount of ferrous sulfate dissolved must be adjusted within an appropriate range to significantly improve the bactericidal effect, and the amount of alkali metal salts, alkaline earth metal salts, or heavy metal salts that are considered to be sterilizing or coating aids should be adjusted to an appropriate range to significantly improve the bactericidal effect. The total of all salts is total 5OIL2-
Indicated by Jl, SO to 200g/cross, preferably 7
Must be in the range of 0-1 SOg/sentence.
この範囲より低い全塩濃度では殺菌能力が劣るようにな
り、またこの範囲より高い濃度では液組成物中に種晶が
析出する等の固形物が発生し、塗布容器中で詰まってし
まい、塗布し難くなる虞れがあり、しかも健康な皮膚を
傷める虞れも出て来る。If the total salt concentration is lower than this range, the bactericidal ability will be inferior, and if the concentration is higher than this range, solid matter such as seed crystals will be generated in the liquid composition, which will clog the coating container and cause the coating to be applied. There is a risk that it will become difficult to clean, and there is also a risk of damaging healthy skin.
また、補助剤としてのアルカリ金属塩としてはナトリウ
ム、カリウム等が、アルカリ土金属塩としてはカルシウ
ムが、重金属塩としては銅、亜鉛、ブンガン等が好まし
く、特に銅が有効である。また、燐(P)塩+N2ガス
あるいはCH。In addition, the alkali metal salts as adjuvants are preferably sodium, potassium, etc., the alkaline earth metal salts are preferably calcium, and the heavy metal salts are copper, zinc, bungan, etc., and copper is particularly effective. Also, phosphorus (P) salt + N2 gas or CH.
等の溶存も殺菌効果を助長する。Dissolution of such substances also promotes the bactericidal effect.
また1本発明の皮膚病治療用液組成物の液密度は約1.
2g/cc程度であり、レドックス酸化還元電位(E
h)は2SO〜400 m Vである。Furthermore, the liquid density of the liquid composition for treating skin diseases of the present invention is about 1.
The redox oxidation-reduction potential (E
h) is 2SO~400 mV.
(ニ)実施例
次に、第1表に示された本発明の液組成物を水中に適用
した実施例を示す。(D) Examples Next, examples will be shown in which the liquid compositions of the present invention shown in Table 1 were applied in water.
(以下余白) そこで、実験結果に基づいて本発明の内容を詳述する。(Margin below) Therefore, the content of the present invention will be explained in detail based on experimental results.
その前に先づ、本発明の液組成物が人体の皮膚に損傷を
与えることがないことを調べるために、準備した浴室清
掃用の短靴中に足を入れ、前記第1表のA液をソーダサ
イフオンを使用して短靴からあふれるまで注入した。Before that, in order to check that the liquid composition of the present invention does not damage human skin, put your feet into the prepared short shoes for cleaning the bathroom, and apply liquid A in Table 1 above. Using a soda siphon, inject until the shoe overflows.
1回目の実験は1分間、2回目は3分間浸漬した。その
結果、足の皮膚表面が黄色となり、乾いてパサパサ状態
となったが、表皮の損傷は全く認められなかった。The first experiment was immersed for 1 minute, and the second experiment was immersed for 3 minutes. As a result, the skin surface of the feet turned yellow and became dry and flaky, but no damage to the epidermis was observed.
次に、A液に10分間浸漬した後、ドライヤーで乾燥さ
せたが、表皮にはまだら模様が現われ、水中にやられて
いる角質層部(以下、巣という)が肉眼で観察されるよ
うになり、各所に点在していることが確認された。Next, after being immersed in Solution A for 10 minutes, it was dried with a hair dryer, but a mottled pattern appeared on the epidermis, and the stratum corneum (hereinafter referred to as nests) damaged by the water became visible to the naked eye. , were confirmed to be scattered in various places.
数時間後には水虫の巣が赤くなって2〜7 am2程度
の斑点状に点在し、約SO時間後には黄色を呈し、7日
後には水虫の巣部位の表皮がはがれ始めた。また、10
日後には表皮はもとに戻り、巣が認められず、かゆみ等
の不快感も全く感じなくなり、白塀菌が殺菌されたもの
と認められた。After several hours, the athlete's foot nest became red and scattered in spots of about 2 to 7 am2, turned yellow after about an hour of SO, and after 7 days, the epidermis at the site of the athlete's foot nest began to peel off. Also, 10
After a few days, the epidermis returned to its original state, no nests were observed, and there was no longer any discomfort such as itching, indicating that the white wall fungus had been sterilized.
(ホ)発明の効果
以上の如く、本発明の液組成物は皮膚病特に水虫の殺菌
に極めて有効であり、該組成物の製造も容易になし得る
利点を特する(E) Effects of the Invention As described above, the liquid composition of the present invention is extremely effective in sterilizing skin diseases, particularly athlete's foot, and has the advantage that the composition can be easily manufactured.
Claims (4)
気の硫酸酸性溶液を主成分とする皮膚病治療用液組成物
。(1) A liquid composition for treating skin diseases whose main component is an acidic sulfuric acid solution in a reducing atmosphere in which ferrous ions and carbon dioxide are dissolved.
c/l以上を溶存するように鉄塩と炭酸塩を水に溶解し
、さらにアルカリ金属、アルカリ土金属又は重金属の塩
の少なくとも1種以上を溶解させた還元性雰囲気の硫酸
酸性水溶液を主成分とし、全SO_4^2−イオンが2
00g/l以下であり、かつpH値が4.0以下に調整
された特許請求の範囲第1項記載の皮膚病治療用液組成
物。(2) Ferrous ion 30g/l or more, carbon dioxide 40c
The main component is an acidic sulfuric acid aqueous solution in a reducing atmosphere in which iron salts and carbonates are dissolved in water so as to dissolve at least c/l, and at least one or more salts of alkali metals, alkaline earth metals, or heavy metals are dissolved. and the total SO_4^2- ions are 2
The liquid composition for treating skin diseases according to claim 1, which has a pH value of 00 g/l or less and a pH value of 4.0 or less.
の中から選ばれる少なくとも1種以上であり、アルカリ
土金属がカルシウム、マグネシウム、ストロンチウム、
バリウム中から選ばれる少なくとも1種以上であり、重
金属が周期率表で示す I 族、II族、V族又はVII族であ
る金属塩の中から選ばれる少なくとも1種以上である特
許請求の範囲第2項記載の皮膚病治療用液組成物。(3) The alkali metal is at least one selected from sodium, potassium, and lithium, and the alkaline earth metal is calcium, magnesium, strontium,
At least one kind selected from barium, and at least one kind selected from metal salts in which the heavy metal is a group I, group II, group V or group VII shown in the periodic table. The liquid composition for treating skin diseases according to item 2.
範囲である特許請求の範囲第1項、第2項又は第3項記
載の皮膚病治療用液組成物。(4) The liquid composition for treating skin diseases according to claim 1, 2 or 3, which has a pH value of 4.0 or less, preferably in the range of 2.0 to 3.5.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10015887A JPS63267724A (en) | 1987-04-24 | 1987-04-24 | Dermatitis treating liquid composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10015887A JPS63267724A (en) | 1987-04-24 | 1987-04-24 | Dermatitis treating liquid composition |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS63267724A true JPS63267724A (en) | 1988-11-04 |
Family
ID=14266508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10015887A Pending JPS63267724A (en) | 1987-04-24 | 1987-04-24 | Dermatitis treating liquid composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS63267724A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5796458A (en) * | 1992-09-01 | 1998-08-18 | Fujitsu Limited | Element division liquid crystal display device and its manufacturing method |
WO1999024043A1 (en) * | 1997-11-07 | 1999-05-20 | Medion Research Laboratories Inc. | Viscous compositions containing carbon dioxide |
-
1987
- 1987-04-24 JP JP10015887A patent/JPS63267724A/en active Pending
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5796458A (en) * | 1992-09-01 | 1998-08-18 | Fujitsu Limited | Element division liquid crystal display device and its manufacturing method |
WO1999024043A1 (en) * | 1997-11-07 | 1999-05-20 | Medion Research Laboratories Inc. | Viscous compositions containing carbon dioxide |
US6689339B1 (en) | 1997-11-07 | 2004-02-10 | Medion Research Laboratories Inc. | Viscous compositions containing carbon dioxide |
EP1574207A1 (en) * | 1997-11-07 | 2005-09-14 | Medion Research Laboratories Inc. | Cosmetic use of viscous compositions containing carbon dioxide |
EP1604646A1 (en) * | 1997-11-07 | 2005-12-14 | Medion Research Laboratories Inc. | Viscous compositions containing carbon dioxide |
EP1604645A1 (en) * | 1997-11-07 | 2005-12-14 | Medion Research Laboratories Inc. | Viscous compositions containing carbon dioxide |
JP2010275322A (en) * | 1997-11-07 | 2010-12-09 | Medion Research Laboratories Inc | Viscous composition containing carbon dioxide |
JP4659980B2 (en) * | 1997-11-07 | 2011-03-30 | 株式会社メディオン・リサーチ・ラボラトリーズ | Carbon dioxide-containing viscous composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Suby et al. | Dissolution of phosphatic urinary calculi by the retrograde introduction of a citrate solution containing magnesium | |
BRPI0414455A (en) | Methods for Using Regenerative Cells to Treat Peripheral Vascular Disease and Related Disorders | |
US20060269615A1 (en) | Topical treatment for skin irritation | |
CN102302510B (en) | Medicinal composition and application thereof | |
DE602004024221D1 (en) | TREATMENT OF INFLAMMATORY ENDURANCE DISEASES WITH 2-METHYLENE-19-NOR-VITAMIN D COMPOUNDS | |
JPS63267724A (en) | Dermatitis treating liquid composition | |
DE3480824D1 (en) | TREATMENT OF MARINE ALGAE TO ACHIEVE DESALINATION ACTIVITY. | |
DE60033830D1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING COPPER, SALICYLIC ACID AND VITAMIN C | |
AU651824B2 (en) | Pharmaceutical composition | |
US6932966B1 (en) | Topically applied reconstituted ocean water mixture and method of producing and using the mixture | |
RU2006114834A (en) | INFUSION DRUG CONTAINING (2R) -2-PROPYLOCTANIC ACID AS AN ACTIVE INGREDIENT | |
US20100099758A1 (en) | Regenerative wound healing using copper-silver citrate composition | |
SU1200903A1 (en) | Method of prophylaxis of complications after urinary tract operation | |
RU2125893C1 (en) | Method of treating surgeon hands | |
JP2002338468A (en) | Footbath product and footbath method | |
JPH03291215A (en) | Bathing liquid containing organic calcium | |
EP0265709A3 (en) | A method and composition for the treatment of bathtubs | |
EA200400783A1 (en) | MEANS FOR RADICAL TREATMENT OF TUMORS, INFLAMMATORY PROCESSES, FUNGAL INFECTIONS AND OTHER TISSUE DISEASES, THEIR DIAGNOSTICS AND PREVENTION AND METHOD OF ITS APPLICATION | |
JPS6229521A (en) | Remedy for superficial mycosis | |
RU2349326C1 (en) | Method of refractory wound treatment in experiment | |
SU895427A1 (en) | Method of treating hoof putrefaction of sheeps and goats | |
RU2187312C1 (en) | Method for treating hoof diseases in farm animals | |
US20030118668A1 (en) | Aquamarine salts based fungicide | |
RU2600033C2 (en) | Method of producing substance for destruction of microvasculature of removed skin formation | |
RU2193409C2 (en) | Method for inactivation of infectious viral and bacterial activity |